IVIM Health vs Maximus: Compounded GLP-1 Pricing and Protocols

How IVIM Health and Maximus differ at a glance

This direct comparison of IVIM Health vs Maximus focuses on five distinctive differences supported by source materials: pricing and promotions, program structure and protocol claims, third-party ratings and track record, medication types and compounding status, and availability and pharmacy sourcing.

1. Pricing and promotional offers

IVIM Health lists a starting price structure that includes compounded semaglutide at $75/mo and tirzepatide at $133/mo plus a $74.99/mo program fee in some materials, and public FAQs note a $99 first month and $174/month ongoing rate. IVIM advertises a no-obligation free consultation valued at $75 and a Free Month Membership with code GIFT75. Maximus publishes a low flat rate of $132.99/month for semaglutide, with statements of starting prices as low as $79.99 in some listings and free priority shipping. Both operate direct-pay models and do not bill insurance according to their materials.

View Maximus pricing and sign-up

2. Program structure and clinical claims

IVIM Health promotes a proprietary GLP-1 ID protocol described as a clinician-guided titration and optimization approach that the company says can accelerate weight loss outcomes by up to 40 percent compared to standard protocols. IVIM cites internal and retrospective observational studies but clearly labels the 40 percent figure as the companys protocol claim and not an independent head-to-head trial. Maximus emphasizes a straightforward semaglutide weight loss protocol delivered by telemedicine, highlighting published semaglutide study averages such as 14.9 percent weight loss over 68 weeks in cited research, while offering custom titration for patients with prior GLP-1 use.

3. Third-party ratings, scale, and track record

IVIM Health reports unusually strong third-party verification with a 4.9-star rating on both Google and Trustpilot, and cites two peer-reviewed retrospective observational studies in Obesity Pillars describing outcomes across branded and compounded formulations. Maximus is presented as a smaller, newer platform with fewer public reviews but with licensed doctors approving prescriptions and medications filled through trusted U.S. pharmacies. The sources indicate IVIM has a larger published patient outcome dataset while Maximus has a thinner public track record.

4. Medication types, compounding, and regulatory notes

Both providers offer compounded medications. IVIM lists compounded semaglutide and tirzepatide options and repeatedly notes that compounded drugs are not FDA-approved and have not undergone FDA review for safety, efficacy, or quality. Maximus offers compounded semaglutide filled in U.S. pharmacies and likewise includes the regulatory note that compounded medications are not FDA-approved. Both providers require clinician review and prescriptions and operate on clinician-guided or licensed-doctor approval models.

5. Availability and pharmacy sourcing

Maximus states medication is compounded in U.S.-based pharmacies, shipped with free expedited or priority options, and is available in all 50 states except Mississippi according to its materials. IVIM notes medications are prepared by independent, licensed compounding pharmacies and that compounded medications are not available in all states; IVIM emphasizes its clinician supervision and membership options. Where Maximus focuses on U.S. pharmacy sourcing and nationwide availability with a state exception, IVIM highlights membership features and clinician oversight.

How to decide between IVIM Health vs Maximus

Choose based only on the documented differences. IVIM Health may be better if you prioritize strong third-party ratings, a structured clinician-guided optimization protocol, and promotional offers like a free $75 consultation and GIFT75 free month. Maximus may be better if you prioritize a predictable low flat monthly price for compounded semaglutide, U.S.-based pharmacy fills, and broad state availability (except Mississippi) with free expedited shipping stated in its materials.

Check Maximus availability and details

Final note: both IVIM Health and Maximus use compounded GLP-1 medications and include regulatory cautions that compounded products are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. The comparison above uses only the providers published statements and supplied evidence. For specific medical questions and eligibility, each company requires clinician review and a prescription.